0001766784-24-000002.txt : 20241022
0001766784-24-000002.hdr.sgml : 20241022
20241022143229
ACCESSION NUMBER: 0001766784-24-000002
CONFORMED SUBMISSION TYPE: D/A
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20241022
DATE AS OF CHANGE: 20241022
EFFECTIVENESS DATE: 20241022
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mediar Therapeutics, Inc.
CENTRAL INDEX KEY: 0001766784
ORGANIZATION NAME:
IRS NUMBER: 832874878
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D/A
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-466474
FILM NUMBER: 241385781
BUSINESS ADDRESS:
STREET 1: 20 OVERLAND STREET
STREET 2: SUITE 520
CITY: BOSTON
STATE: MA
ZIP: 02215
BUSINESS PHONE: 617-936-0960
MAIL ADDRESS:
STREET 1: 20 OVERLAND STREET
STREET 2: SUITE 520
CITY: BOSTON
STATE: MA
ZIP: 02215
D/A
1
primary_doc.xml
X0708
D/A
LIVE
0001766784
Mediar Therapeutics, Inc.
20 OVERLAND STREET
SUITE 520
BOSTON
MA
MASSACHUSETTS
02215
617-936-0960
DELAWARE
None
None
Corporation
true
Rahul
Ballal
c/o Mediar Therapeutics, Inc.
20 Overland Street, Suite 520
Boston
MA
MASSACHUSETTS
02215
Executive Officer
Director
Cassidy
Blundell
c/o Mediar Therapeutics, Inc.
20 Overland Street, Suite 520
Boston
MA
MASSACHUSETTS
02215
Director
Michael
Baran
c/o Mediar Therapeutics, Inc.
20 Overland Street, Suite 520
Boston
MA
MASSACHUSETTS
02215
Director
Meredith
Fisher
c/o Mediar Therapeutics, Inc.
20 Overland Street, Suite 520
Boston
MA
MASSACHUSETTS
02215
Director
Maina
Bhaman
c/o Mediar Therapeutics, Inc.
20 Overland Street, Suite 520
Boston
MA
MASSACHUSETTS
02215
Director
Andreas
Jurgeit
c/o Mediar Therapeutics, Inc.
20 Overland Street, Suite 520
Boston
MA
MASSACHUSETTS
02215
Director
Anja
Konig
c/o Mediar Therapeutics, Inc.
20 Overland Street, Suite 520
Boston
MA
MASSACHUSETTS
02215
Director
Simon
Sturge
c/o Mediar Therapeutics, Inc.
20 Overland Street, Suite 520
Boston
MA
MASSACHUSETTS
02215
Director
Biotechnology
Decline to Disclose
- 06b
true
0001766784-23-000002
2022-11-18
false
true
false
0
85034866
85034866
0
false
17
0
0
0
false
Mediar Therapeutics, Inc.
/s/ Rahul Ballal
Rahul Ballal
Chief Executive Officer
2024-10-22